Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567032 · ClinicalTrials.gov registry record · Early Phase 1
Adult Study Oxytocin - Behavioral
A Early Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 324
- Enrollment target
NCT02567032: Completed Early Phase 1 study, sponsored by University of California, San Francisco.
NCT02567032 is a Early Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 324 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (511% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02567032, a Early Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 324 participants
- Enrollment target
Study Summary
In this study, investigators will examine the behavioral effects and neurophysiological mechanisms of the pro-social neuropeptide oxytocin in patients with recent-onset schizophrenia and other psychotic disorders. Such research is a necessary first step towards identifying whether intranasal oxytocin administration can serve as an adjunct treatment for social impairments in schizophrenia and other psychotic disorders. Aim 1: To quantify the effects of exogenous oxytocin on social cognition and behavior in patients with recent-onset schizophrenia. Hypothesis A: Patients and healthy comparison subjects will show enhanced social cognition (e.g., improved interpretation of paralinguistic and emotional cues, such as those involved in emotional or sarcastic communication) after administration of oxytocin versus placebo. Hypothesis B: Patients and healthy comparison subjects will show increased attention to others' eyes and patients will exhibit increased facial affect expressivity after administration of oxytocin versus placebo.
Primary Outcome
Participants will undergo computer tasks that measure social cognition. Tasks will involve verbal responses, pressing buttons at specific times, listening, and viewing audio-visual stimuli. Investigators will be measuring the difference in accuracy and verbal content of the responses on the oxytocin day compared to the placebo day.
Interventions
- DRUG Oxytocin
- DRUG Saline Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2010-10 |
| Est. Completion | 2019-08 |
| Phase | Early Phase 1 |
What the finished NCT02567032 record still lists
NCT02567032 is an interventional study that assigns participants to a tested intervention. The registered 324 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (511% higher).
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT02567032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02567032 about?
NCT02567032 is a clinical study titled "Adult Study Oxytocin - Behavioral". In this study, investigators will examine the behavioral effects and neurophysiological mechanisms of the pro-social neuropeptide oxytocin in patients with recent-onset schizophrenia and other psychotic disorders. Such research is a necessary first step towards identifying whether intranasal oxytoci...
What is the current status of trial NCT02567032?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 324 participants. The study started on 2010-10. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02567032?
The interventions under investigation include: Oxytocin (DRUG), Saline Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT02567032?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02567032's enrollment target sits among peer trials
324 33rd of 2000 higher than 1,968 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia